RCKT Q1 2022 Earnings — Rocket Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RCKTRocket Pharmaceuticals, Inc.

$572M

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$43M

Net Income

-$43M

EPS (Diluted)

$-0.67

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$39M

Free Cash Flow

-$41M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$460M

Total Liabilities

$43M

Stockholders' Equity

$418M

Cash & Equivalents

$131M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$43M	-$39M	-8.5%
Net Income	-$43M	-$40M	-7.0%